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E-mail address:wolfgang.wohlleben@biotech.uni-tActinomycetes are a rich source for the synthesis of medically and technically useful natural prod-
ucts. The genes encoding the enzymes for their biosynthesis are normally organized in gene clusters,
which include also the information for resistance (in the case of antibacterial compounds), regula-
tion, and transport. This facilitates the manipulation of such pathways by molecular genetic tech-
niques. Recent advances in DNA sequencing and analytical chemistry revealed that not only new
strains isolated from yet unexplored habitats, but also already known strains possess a large poten-
tial for the synthesis of novel compounds. Synthetic Biology now offers a new perspective to exploit
this potential further by generating novel pathways, and thereby novel products, by combining dif-
ferent biosynthetic steps originating from different bacteria.
The supply of precursors, which are subsequently incorporated into the ﬁnal product, is often
already organized in a modular manner in nature and may directly be exploited for Synthetic Biol-
ogy. Here we report examples for the synthesis of building blocks and possibilities to modify and
optimize antibiotic biosynthesis, exemplary for the synthesis of the manipulation of the synthesis
of the glycopeptide antibiotic balhimycin.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Bacteria of the order Actinomycetales are – together with myxo-
bacteria – the most proliﬁc producers of microbial secondary
metabolites [1]. A majority of these metabolites have interesting
biological activities and are used in medicine, agriculture, and
industry [2]. In particular, many compounds exhibit antiinfective
properties. But only about 100 of them are used in different appli-
cations, such as therapeutics to combat bacterial, viral or fungal
infections, as herbicides, growth promoting agents or valuable
tools in biochemical research.
In many cases, the naturally synthesized molecules are less use-
ful than chemical derivatives. Often modiﬁcations are required to
optimize the microbial metabolites with respect to solubility, phar-
macokinetic properties or toxicity. A further bottleneck, which lim-
its the application of newly identiﬁed antibiotics, is the low
product yield obtained from natural isolates: whereas production
rates in the range of g/l are needed to set up a cost effective pro-
duction process, wild type strains normally only produce in the
mg/l range or less. To overcome the yield problem in industry,
mostly ‘‘classical’’ approaches are applied, which include repeatingcal Societies. Published by Elsevier
uebingen.de (W. Wohlleben).rounds of mutation and selection as well as improved fermentation
and downstream processing technologies.
The generation of optimized derivatives is mostly based on
medicinal chemistry or even total synthesis technologies. Progress
in genome research and in analyzing secondary metabolite
pathways, as well as Synthetic Biology technologies, already suc-
cessfully applied for several bacteria [3,4], offer alternative
approaches for generating novel compounds and improving the
yield. In recent years, several 100 biosynthetic pathways for antibi-
otics have been elucidated in detail. This led to a comprehensive
knowledge on the general principles of these biosyntheses and a
huge collection of enzymes (and genes, respectively) involved in
all types of chemical conversions. Furthermore, more than 20 com-
plete or high quality draft genome sequences and several hundred
partial sequences of actinomycetes are deposited in data bases
(National Center for Biotechnology Information, NCBI); in addition
dozens of partial genome sequences are available or are being cur-
rently under investigation. Using recently developed bioinformatic
tools [5–7], these genome data can be easily and efﬁciently
screened for the presence of secondary metabolite pathways,
which then can subsequently be isolated. This knowledge and
these resources now allow applying Synthetic Biology approaches
to both, the generation of novel antibiotics and the optimization
of their yield. Novel compounds may be obtained by heterologous
expression of newly identiﬁed pathways in optimized hosts [8] orB.V. Open access under CC BY-NC-ND license.
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thetic routes. The perspectives of such approaches have been de-
scribed in a number of recently published reviews [9,10] and will
not be illustrated in this contribution.
We will concentrate on the opportunities that can be offered by
a Synthetic Biology approach dedicated to the precursor supply. On
the one hand, the incorporation of the precursor deﬁnes the chem-
ical structure of the end product and its manipulation may serve as
a possibility to generate chemical diversity. On the other hand, pre-
cursor supply is a crucial factor, which determines the ﬁnal yield.
The comparisons of secondary metabolite gene clusters indicate
that Synthetic Biology experiments in the lab copy processes,
which are ongoing in nature since millions of years. Whereas the
in vitro techniques rely on sophisticated genetic and biochemical
tools, the in vivo system depends on a highly efﬁcient gene transfer
process, which may serve as a blueprint for new strategies in Syn-
thetic Biology.2. Precursor biosynthesis: analysis and its potential for
generating diversity
The majority of the core structures of antibiotics are either syn-
thesized by non-ribosomal peptide synthetases (NRPS), polyketide
synthases (PKS) or by hybrid enzymes thereof [11–13]. As building
blocks mainly amino acids or acyl-CoA molecules are required,
which are supplied by the primary metabolism. However, often
also alternative precursors can be incorporated, such as non-pro-
teinogenic amino acids or unusual acyl-CoA variants, of which
the biosynthesis is an integral part of the speciﬁc secondary metab-
olite biosynthesis and starts most likely with intermediates of the
primary metabolism. Exchanging pathways for the supply of build-
ing blocks may lead to the generation of novel compounds. A pre-
condition for such experiments is a deeper knowledge on their
synthesis and the genetic organization of the respective genes. As
an example, we describe the synthesis of the three non-proteino-
genic amino acids (b-hydroxytyrosine (b-Ht), hydroxyphenylgly-
cine (Hpg), and dihydroxyphenylglycine (Dpg)) incorporated in
glycopeptides and phenylglycine (Phg), a non-proteinogenic amino
acid in the streptogramin antibiotic pristinamycin.
2.1. b-Ht-, Hpg- and Dpg-synthesis in glycopeptides
Glycopeptides, such as vancomycin, are the drugs of last resort
against antibiotic resistant gram-positive bacteria. The best ana-
lyzed strain for glycopeptide biosynthesis is Amycolatopsis balhimy-
cina, the producer of the vancomycin-type glycopeptide
balhimycin [14]. Glycopeptides of the vancomycin-type consist of
a heptapeptide backbone including ﬁve aromatic amino acids,
which are linked by diaryl-ether and diaryl bonds, respectively.
Further modiﬁcations occurring at the backbone are, besides oth-
ers, glycosylation, halogenation and methylation [15].
A 66-kb gene cluster encoding the biosynthesis of balhimycin
was identiﬁed and sequenced [16,17]. By a combination of genet-
ics, biochemistry, and analytical organic chemistry the function
of nearly all genes of the cluster and therewith the biosynthetic
pathway has been elucidated [18,19]. The biosynthesis starts with
the pathway-speciﬁc supply of the non-proteinogenic amino acids
b-Ht, Hpg, and Dpg, which together with (N-methyl)-leucine and
asparagine form the heptapeptide backbone of balhimycin.
In the balhimycin biosynthetic gene cluster three genes (pgat,
hmaS, and hmo) are located that encode proteins, which show sig-
niﬁcant similarity to enzymes of the Hpg synthesis of the chloroe-
remomycin producer Amycolatopsis orientalis and of all other
glycopeptide producers. Biochemical analysis revealed that Hpg
biosynthesis proceeds from prephenate via hydroxyphenylpyru-vate, hydroxybenzoylformate, and hydroxymandelate to Hpg
[20]. Based on the high similarity of the respective enzymes, an
analogous biosynthetic pathway was postulated for the Hpg-bio-
synthesis in A. balhimycina [18].
Besides that, three genes (bhp, bpsD, and oxyD) which are re-
quired for the biosynthesis of b-Ht are localized in the balhimycin
biosynthetic gene cluster. They encode the perhydrolase, Bhp, the
NRPS-like module, BpsD, and the monooxygenase, OxyD. The pro-
posed model suggests that tyrosine is loaded onto BpsD with a sub-
sequent b-hydroxylation of the BpsD-bound tyrosine catalyzed by
OxyD [21]. The last step is the hydrolysis of b-Ht from the BpsD
complex due to the action of the hydrolase Bhp in order to deliver
the free amino acid [22,23].
The non-proteinogenic amino acid Dpg is synthesized via a
polyketide synthase mechanism (PKSIII) similar to that known
from plant chalcone/stilbene synthases. Four genes, forming an op-
eron (dpgABCD), are required to provide Dpg, which is synthesized
from four molecules of malonyl-CoA [24]. The ﬁnal step in the
pathway of Dpg is the transamination by the same enzyme (Pgat)
that was shown to catalyze the ﬁnal step in Hpg biosynthesis. Sim-
ilar to Hpg, the formation of Dpg requires tyrosine as amino donor
[24].
However, the individual ‘‘gene sets’’ required for the synthesis
of the non-proteinogenic amino acids are co-transcribed each
and are even translationally coupled in some cases. This offers an
easy way to clone and to express these genes in order to make
the building blocks available for the synthesis of other complex
molecules, in which these amino acids may be incorporated. The
operon-like structure also makes it possible to jointly transfer
the ability to produce these unusual amino acids in on step from
one bacterium to another.
2.2. Phg synthesis in streptogramin antibiotics
Similarly to glycopeptides, streptogramin antibiotics such as
Synercid are used to combat multi-resistant gram-positive patho-
gens. Synercid is a mixture of two chemically different com-
pounds, pristinamycin I (PI) and pristinamycin II (PII), produced
by Streptomyces pristinaespiralis. PI is a cyclic hexadepsipeptide,
which is coproduced with the macrolactone-like compound PII.
The synthesis of PI is performed by three NRPSs, SnbA, SnbC, and
SnbDE, of which SnbDE is responsible for the introduction of the ﬁ-
nal amino acid phenylglycine (Phg) into the growing peptide chain
[25]. In analogy to glycopeptide biosyntheses, amino acid supply
can be the starting point for manipulation of antibiotic production
by Synthetic Biology. The genes that encode the biosynthesis of
Phg (pglA, pglB, pglC, pglD, and pglE) are organized in an operon-like
structure together with the NRPS gene snbDE on the large 210 kb
pristinamycin supercluster [26,27]. For the biosynthesis of Phg,
phenylpyruvate, which is a compound derived from the shikimate
pathway of primary metabolism, most likely serves as the precur-
sor. Phenylpyruvate is turned into phenylacetyl-CoA by the action
of the pyruvate dehydrogenase-like complex PglB/C (Fig. 1). This
reaction step is supposed to resemble the enzymatic reaction of
the primary metabolic pyruvate dehydrogenase reaction, which
forms acetyl-CoA out of pyruvate and by this means links glycoly-
sis to the citric acid cycle [27].
The beginning of Phg synthesis strongly differs from that of the
related Dpg pathway of A. balhimycina. Here, the corresponding
product dihydroxyphenylacetyl-CoA is formed out of four units
of malonyl-CoA, which are enzymatically condensed by the PKS
DpgA and the hydratases DpgB and DpgD [24]. During Phg biosyn-
thesis of S. pristinaespiralis phenylacetyl-CoA is probably converted
to benzoylformyl-CoA by PglA, which is an enzyme that is highly
similar to the hydroxyacyl-dehydrogenase (dioxygenase) DpgC of
A. balhimycina and other glycopeptide producers [27]. DpgC is an
Fig. 1. Biosynthetic pathway of phenylglycine (a) and dihydroxyphenylglycine (b). The two pathways are placed on top of each other to illustrate the similarity of the
respective reactions.
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verts dihydroxyphenylacetyl-CoA to the penultimate intermediate
dihydroxyphenylglyoxylate [28]. During this reaction step the
CoA-thioester is cleaved of by the DpgC enzyme [28]. This is in con-
trast to the Phg pathway of S. pristinaespiralis, where the coenzyme
A residue may be released from benzoylformyl-CoA by the action
of a separate thioesterase, PglD, which leads to the corresponding
product phenylglyoxylate [27]. Finally, both intermediates under-
go a transamination event, which is catalyzed by the aminotrans-
ferases PglE (Phg pathway) and Pgat (Dpg pathway), respectively
(Fig. 1). Both enzymes show high similarity to each other and their
reactions leads to the end-products Phg and Dpg (and Hpg), respec-
tively [24,27]. In terms of PI biosynthesis of S. pristinaespiralis, Phg
is subsequently introduced by the NRPS SnbDE into the linear pep-
tide chain, which also catalyzes the ﬁnal cyclization event resulting
in PI.
As both non-proteinogenic amino acid gene sets (Dpg and Phg
pathway) are presumably co-transcribed, the simple exchange of
the balhimycin Dpg operon by the PI speciﬁc Phg operon may lead
to a novel glycopeptide derivative. Such a lego-like reconstruction
of known secondary metabolite pathways may lead to a broad
spectrum of new substances with potential attractive activities.
Interestingly, the biosynthesis of the two similar chemical sub-
stances, Phg and Dpg, starts from completely different precursors
and by using different starting enzymes, whereas the internal syn-
thetic events and enzymes, such as the dioxygenase reactions (cat-
alyzed by PglA and DpgC) and the aminotransferase reactions
(catalyzed by PglE and Pgat) resemble each other. A further inter-
esting feature of these pathways is that the enzymes that are in-
volved in the biosynthesis of secondary metabolite speciﬁc
amino acids are signiﬁcantly similar to enzymes of the primary
metabolism. For balhimycin biosynthesis this was also observed
for the enzymes prephenate dehydrogenase (Pdhsec) and 3-
deoxy-D-arabino-heptulosonate-7-phosphate synthase (DAHPsec),
which are involved in biosynthesis of Hpg and chloro-hydroxytyro-
sine (see below) and are similar to enzymes of the shikimate path-
way (see also Section 3.2), whereas in S. pristinaespiralis the above
mentioned enzyme complex PglB/C is responsible for Phg biosyn-
thesis and strongly resembles the primary metabolic pyruvate
dehydrogenase. These examples let us assume that primordial
gene duplication events were the beginning of such enzyme evolu-
tions. The newly acquired isoenzyme genes then probably have
undergone further mutations, which led to a broader substrate
speciﬁcity of the respective enzymes. Finally, these enzymes could
be used elsewhere, e.g. for the biosynthesis of non-proteinogenicamino acids, which are utilized for secondary metabolite produc-
tion. From the evolutionary point of view such a progression of en-
zyme development is quite reasonable, since when a new enzyme
variant emerges by mutation, it usually has a different substrate
speciﬁcity than the wild-type enzyme but not a different type of
chemical catalysis [29].
Due to these observations one can hypothesize that biosyn-
thetic steps of the primary metabolism may be used (directly or
after directed evolution) for the supply of building blocks to be
incorporated in secondary metabolites by Synthetic Biology.3. Engineering precursor biosynthesis for optimizing antibiotic
production
Based on the knowledge how antibiotic biosynthesis proceeds,
Synthetic Biology can aim to optimize antibiotic production in
two ways: Either biosynthesis genes from different origin can be
mixed to generate novel pathways (and products thereof), or spe-
ciﬁc steps (preferred precursor supply) can be manipulated to
overcome bottlenecks in order to improve the yield.
3.1. Generation of novel derivatives
The approaches by which derivatives of natural compounds
were mostly synthesized up to now rely on chemical techniques.
They have been proven to be very powerful for the generation of
derivatives with chemically attached side-groups (like acetyl-,
methyl-groups, sugars etc.). For attaching novel side groups or
changing modiﬁcation patterns Synthetic Biology-like approaches
have also successfully been applied for many years [10].
In contrast, severe restrictions exist if the backbone of a com-
plex natural product has to be altered by chemical methods. How-
ever, the understanding for the biosynthetic principles of NRPS and
PKS enzymes, which form huge multienzyme complexes (e.g. [18])
offer alternatives for ‘‘biological approaches’’. These modular en-
zymes condense building blocks stepwise in an assembly-line fash-
ion to generate a peptide or a polyketide backbone [12,13]. The
adenylation- or the acyl-transfer domains of these enzymes,
respectively, determine which building block has to be incorpo-
rated in a certain step. This can be used to exchange or combine
different domains in a ‘‘lego-like’’ approach to reprogram the en-
zymes for making altered or even extended backbones. The poten-
tial of such approaches has been described in several reviews
[30,31], but its routine application still suffers from several
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domains, which have to be known to generate functional fusions.
Furthermore, newly constructed NRPS or PKS enzymes mostly pro-
duce only small amounts of natural compounds. But the already
existing knowledge indicates that optimized Synthetic Biology en-
zymes may be used in future for the creation of new pathways.
So we could show for balhimycin that the insertion of an extra
module in the peptide synthetase BpsB [32] leads to the production
of an octapeptide consisting of a additional Hpg. Although this new
balhimycin derivate has no biological activity this example may be
regarded as a precursor to the lining up of modules for the synthe-
sis of any arbitrarily chosen amino acid sequence [33] (Fig. 2).
Surprisingly, there is a relaxed speciﬁcity of some recognition
domains, in particular those of the adenylation domains. If com-
pounds resembling the natural substrates are provided instead of
the original substrates these ‘‘unnatural’’ building blocks will be
readily incorporated. This can be exploited in different ways. On
one hand, mutants that cannot synthesize a speciﬁc precursor
can be cultivated in the presence of alternative amino acids. In
such a ‘‘precursor-directed biosynthesis’’ approach, glycopeptides,
in which either Dpg [34] or Chloro-b-Ht [35] were replaced by
alternative amino acids, were generated and shown to be active
[36]. On the other hand, this can easily be extended by using these
mutants as recipients in cloning experiments, where genes respon-
sible for the synthesis of novel precursor amino acids are intro-
duced. Precursor supply is proceeding in the cytoplasm without
physical interaction between the enzymes involved in precursor
synthesis and the multienzyme complex responsible for connect-
ing the precursors. Therefore, the construction of novel artiﬁcial
pathways by Synthetic Biology approaches is not limited by any
incompatibility of protein–protein interplay.
3.2. Increasing yield
Antibiotics require precursors, which are mainly provided by
the primary metabolism. As long as the bacteria are in their expo-
nential growth phase, building blocks, such as amino acids, acyl-
CoA or sugars are used to build up biomass. As soon as the bacteria
enter the stationary phase, secondary metabolism is initiated andFig. 2. Schematic representation of a ‘‘Lego-like’’ approach for precursor-driven Synthetic
and blue symbols, respectively. Modiﬁcations are labelled as dark blue spheres. Unn
heptapeptide backbone of the glycopeptides antibiotic and the side-chain cross-linkagethe bacteria start to produce the particular peptide antibiotics,
polyketides or aminoglycosides, or a speciﬁc selection of these
building blocks is taken to synthesize the respective antibiotic
(Fig. 2). This makes it necessary to redirect the primary metabolism
to certain precursors and – sometimes – to synthesize additional
precursors as non-proteinogenic amino acids, new acyl-CoA vari-
ants or alternative nucleotide-activated desoxysugars. This part
of the metabolism is a suitable target for engineering the biosyn-
thesis to increase the yield [37]. Here, also glycopeptide biosynthe-
sis can serve as a paradigm for studying precursor biosynthesis and
their manipulation by Synthetic Biology approaches.
Since in glycopeptide biosynthesis tyrosine and hydroxyphenyl-
pyruvate are the precursors for the non-proteinogenic amino acids
b-Ht and Hpg, respectively, the primary metabolic shikimate path-
way plays an important role in the supply of these precursors.
Especially tyrosine has a key role in precursor supply as it is the
amino donor in Dpg biosynthesis [3].
The key enzymes of the shikimate pathway are the 3-deoxy-D-
arabino-heptulosonate-7-phosphate (Dahp) synthase and the pre-
phenate dehydrogenase (Pdh). Dahp condenses the pentose phos-
phate pathway intermediate D-erythrose 4-phosphate and the
glycolytic pathway intermediate, phosphoenolpyruvate, to Dahp.
The Pdh catalyses the conversion of prephenate into 4-hydroxy-
phenylpyruvate and directs ﬂux towards tyrosine biosynthesis.
In Synthetic Biology approaches these reactions have to be en-
hanced in order to obtain a yield increase. The problem is that in
the bacterial primary metabolism aromatic amino acid biosynthe-
sis is strictly regulated via feedback control mechanisms. There-
fore, antibiotic biosynthesis may require speciﬁc metabolic
adaptations, e.g. expression of isoenzymes that avoid this feedback
regulation [38]. Genetic analyses revealed that in addition to the
genes pdhprim and dahpprim, which encode the primary metabolic
enzymes, the balhimycin gene cluster includes two further copies
of these genes (pdhsec and dahpsec). We assume that Pdhsec and
Dahpsec are responsible for the optimal provision of tyrosine as
precursor for the biosynthesis of the non-proteinogenic amino
acids b-Ht, Hpg, and Dpg. The dahpsec and pdhsec genes from the
biosynthetic cluster were overexpressed, both, individually and to-
gether. The pdhsec overexpression strain as well as the pdhsecBiology. Compounds of the primary and secondary metabolism are shown as green
atural precursors are shown as black symbols. Black and red lines represent the
s, respectively.
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the wild type strain. The recombinant strains expressing additional
copies of the dahpsec gene showed improved glycopeptide produc-
tivities by approximately a factor of three [39]. Thus, we demon-
strated that the existence of isoenzymes is an example that in
some cases nature anticipates Synthetic Biology. Such overexpres-
sion approaches that increase precursor supply have a great poten-
tial to optimize antibiotic production.
Interestingly, thepdh gene is also conservedwithin the glycopep-
tide biosynthesis gene clusters of chloroeremomycin (cep), dalba-
vancin (dbv), complestatin (sta), and teicoplanin (tcp), whereas
dahp exists only in the bal and cep cluster; furthermore, pdh- and
dahp-paralogous genes have been identiﬁed in the phosphinothricin
biosynthetic gene cluster of Streptomyces viridochromogenes [40]
and dahp is also present in the gene clusters of the ansamycin antibi-
otics rifamycin, ansatrienin (mycotrienin), and naphthomycin [40].
Thus, manipulation of precursor supply in all these strains can be
used as a common method to raise antibiotic production levels.
4. Impact of lateral gene transfer on the evolution and diversity
of biosynthetic gene clusters
The comparison of the biosynthetic gene clusters for the differ-
ent glycopeptide pathways revealed the presence of conserved
genes, which are needed to synthesize the core structure of a gly-
copeptide [18,41]. Whereas the overall order of the genes is not the
same in the clusters, a certain ‘‘suborder’’ of these core genes can
be observed. For example groups of genes encoding enzymes in-
volved in the synthesis of a speciﬁc precursor are usually co-lo-
cated, and are supposed to be co-transcribed. For example, the
genes dpgABCD encoding the enzymes for Dpg synthesis, are al-
ways positioned next to each other and most likely are translation-
ally coupled. These genes are even present in the same
organization and as an individual operon in the genome of bacteria,
which are known to do not synthesize glycopeptides (Weber,
unpublished). This leads to the hypothesis that such ‘‘sub-operons’’
are rather widely distributed in bacteria and may serve as genetic
building blocks, which can be combined to novel pathways. How-
ever, to achieve such ‘‘synthetic’’ approaches in nature, a highly
effective system to mix genes from different bacteria is required.
This system may be provided by a special conjugation process,
which transfers genes with high rates and seems to be unique for
some actinomycetes.
Antibiotic producing actinomycetes developed a distinct conju-
gative DNA-transfer system, which is completely different from the
conjugation process described in textbooks [42]. Even small plas-
mids, e.g. pSVH1 from the chloramphenicol producer Streptomyces
venezuelae of only 8–15 kb in size are self-transmissible [43]. A sin-
gle plasmid-encoded protein, TraB, is sufﬁcient to direct transfer of
a double-stranded plasmid molecule with an efﬁciency of nearly
100%. Simultaneously, in about 0.1–1% of the transconjugants
chromosomal genes are co-transferred [44,45].
Domain architecture, sequence similarity, structure of the DNA
translocase domain, and the mode of DNA recognition groups TraB
to the septal DNA translocator proteins of the FtsK/SpoIIIE family.
These proteins translocate chromosomal DNA during cell division
and sporulation in a polar manner by recognizing 8 bp KOPS (FtsK
Orienting Polar Sequences) sequences that have a biased distribu-
tion on bacterial genomes. Similarity of TraB to FtsK suggests that
conjugative DNA transfer in antibiotic producing actinomycetes
resembles the segregation of chromosomal DNA during cell divi-
sion. However, whereas FtsK translocates DNA between two cellu-
lar compartments, TraB has to transfer DNA between two distinct
cells.TraB of plasmid pSVH1 has been shown to oligomerize to a ring-
shaped hexamer with a central channel of about 31 nm in size. Sin-
gle channel recordings in planar lipid bilayers revealed a pore
forming activity of TraB [45]. During transfer, TraB binds to a spe-
ciﬁc plasmid region, clt, thus recognizing only its cognate plasmid
[46]. This region is non-coding, has a size of 50–170 bp and con-
tains a series of direct 8 bp TRS (TraB-recognition sequence) re-
peats, which are speciﬁc for a given plasmid. Gel retardation
experiments with synthetic oligonucleotides demonstrated spe-
ciﬁc TraB binding to TRS. In a synthetic approach chimeric TraB
proteins were generated by combining fragments of traB genes
from different Streptomyces plasmids and the sequence-speciﬁc
DNA binding activity of the respective proteins was analyzed.
These analyses demonstrated that exchange of only 13 amino
acids, corresponding to helix a3 of the C-terminal winged helix
turn helix fold of TraB was sufﬁcient to switch speciﬁcity of clt rec-
ognition [45,47].
Interestingly, clt-like sequences also occur in Streptomyces chro-
mosomes (clc). S. coelicolor contains 25 statistically distributed
cltpSVH1-like sequences. As TraB has been demonstrated to bind
in vitro [45] and in vivo (unpublished results) to clc sites, transfer
of chromosomal genes might be mediated by the interaction of
TraB with chromosomal clc sites [48]. This is in contrast to the well
characterized conjugation systems (e.g. HFR), where mobilization
of chromosomal markers depends on the preceding plasmid inte-
gration close to the mobilized genes.
Such a mobilization system not relying on plasmid integration
might have stimulated the transfer of chromosomal genes result-
ing in mixing and matching of building blocks for new biosynthetic
clusters suggesting that nature is already using ‘‘Synthetic Biology’’
approaches to shape and optimize pathways. Based on a deep
understanding of this transfer system further studies will aim to
exploit it for the generation of newly combined biosynthetic gene
clusters by ‘‘in vivo Synthetic Biology’’.
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